TVTX

Travere Therapeutics Inc. Common Stock (TVTX)

Stock · NASDAQ · Health Care

$49.62as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 9, 2026

Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.

Price chart

Open in TradingView

Active signals

Support Reject13.6%200 SMA Touch0.0%
Resistance level
$54.91
Industry
Biotechnology: Pharmaceutical Preparations

TVTX Signal Track Record

How signals performed across all stocks →

What TVTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike38+5.4%66%
Bollinger Band Breakout27+5.6%63%
Bollinger Band Breakdown14+2.9%57%
200-Day Moving Average TouchActive now8-12.3%38%
Any 20-session window (baseline)+1.2%53%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopron…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
497

Fundamentals

1-day range
$49.46$52.56
Market cap
$5.89B
P/E (trailing)
—
P/E (forward)
8.80
EPS (trailing)
$-0.50
Dividend yield
—
Beta
1.08
Avg. volume
1.64M
52-week range
$22.59$68.73
Next earnings: October 29, 2026 · EPS estimate $0.49confirmed

How Travere Therapeutics Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$490.73MSG&A$337.20M (69%)Other$142.20M (29%)Cost of Revenue$10.34M (2%)Tax$988.0K (0%)TVTX

Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub

Gross Profit$480.39M(98%)
Operating Income-$62.82M(-13%)

Forecasts

14 analyst ratings

Buy 91%
Hold 10%
Sell 0%
1-year price forecast
High
$90
+81.4%
Median
$75.5
+52.2%
Low
$62
+25.0%

Travere Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • TVTX
    Travere Therapeutics Inc. Common Stock
    $49.6
    ▼ 6.04%
    Market cap $5.89BP/E —
    $22.59$68.73
  • PTCT
    PTC Therapeutics Inc. Common Stock
    $59.24
    ▼ 2.87%
    Market cap $5.91BP/E —
    $58.8$90.87
  • KNSA
    Kiniksa Pharmaceuticals International plc Class A Ordinary Shares
    $78.59
    ▼ 1.69%
    Market cap $5.97BP/E 77.33
    $35.2$82.94
  • AMRX
    Amneal Pharmaceuticals Inc. Class A Common Stock
    $19.18
    ▼ 0.36%
    Market cap $5.76BP/E 39.88
    $9.56$21.18
  • LGND
    Ligand Pharmaceuticals Incorporated Common Stock
    $295.54
    ▼ 0.99%
    Market cap $6.02BP/E 30.38
    $175.89$326.63
  • MIRM
    Mirum Pharmaceuticals Inc. Common Stock
    $80.14
    ▼ 2.73%
    Market cap $5.74BP/E —
    $63.23$130
  • DNTH
    Dianthus Therapeutics Inc. Common Stock
    $72.09
    ▼ 3.27%
    Market cap $6.15BP/E —
    $32.22$117.88

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Insider Activity

Insider Actions →
Acquired
597.8K
Disposed
485.3K
  • Heerma Peter · September 17, 2026 · Option Exercise
    8.3K @ $22.4
  • Heerma Peter · September 17, 2026 · Sale
    8.3K @ $65.07
  • Dube Eric M · September 17, 2026 · Option Exercise
    108.5K @ $23.34
  • Dube Eric M · September 17, 2026 · Sale
    6.8K @ $64.95
  • Dube Eric M · September 17, 2026 · Sale
    101.7K @ $64.59
  • Heerma Peter · September 16, 2026 · Option Exercise
    17.7K @ $26.88
  • Heerma Peter · September 16, 2026 · Option Exercise
    55.0K @ $15.46
  • Heerma Peter · September 16, 2026 · Option Exercise
    100.0K @ $11.25
  • Heerma Peter · September 16, 2026 · Sale
    79.1K @ $63.65
  • Heerma Peter · September 16, 2026 · Sale
    93.6K @ $63.25
  • Dube Eric M · September 16, 2026 · Option Exercise
    195.8K @ $23.34
  • Dube Eric M · September 16, 2026 · Sale
    96.1K @ $63.64
  • Dube Eric M · September 16, 2026 · Sale
    99.7K @ $63.26
  • ROTE WILLIAM E. · September 16, 2026 · Option Exercise
    57.5K @ $26.88
  • ROTE WILLIAM E. · September 16, 2026 · Option Exercise
    55.0K @ $15.46

Institutional Ownership

March 31, 2026

Total shares held
102.91M
Total value held
$3.01B
Institutional holders
255
Top holders this quarter
  • Unknown11.42M
  • Unknown10.97M
  • Unknown7.79M
  • Unknown4.96M
  • Unknown4.90M
  • Unknown4.14M
  • Unknown4.05M
  • Unknown3.27M
  • Unknown2.42M
  • Unknown2.37M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.